{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:18:38Z","timestamp":1793409518288,"version":"4.5.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>While the incidence of early-onset metastatic colorectal cancer (mCRC) has been increasing, studies on the age-related disparity in this group of patients are limited.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the association of age with treatment-related adverse events and survival in patients with mCRC and explore the potential underlying factors.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study included 1959 individuals. Individual data on 1223 patients with mCRC who received first-line fluorouracil and oxaliplatin therapy in 3 clinical trials, and clinical and genomic data of 736 patients with mCRC from Moffitt Cancer Center were used to assess genomic alterations and serve as an external validation cohort. All statistical analyses were conducted from October 1, 2021, through November 12, 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Metastatic colorectal cancer.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Survival outcomes and treatment-related adverse events were compared among patients in 3 age groups: younger than 50 (early onset), 50 to 65, and older than 65 years.<\/jats:p><\/jats:sec>Results<\/jats:title>In the total population of 1959 individuals, 1145 (58.4%) were men. Among 1223 patients from previous clinical trials, 179 (14.6%) in the younger than 50 years group, 582 (47.6%) in the 50 to 65 years group, and 462 (37.8%) in the older than 65 years group had similar baseline characteristics except for sex and race. The younger than 50 years group had significantly shorter progression-free survival (PFS) (hazard ratio [HR], 1.46; 95% CI, 1.22-1.76; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and overall survival (OS) (HR,\u20091.48; 95% CI, 1.19-1.84; P<\/jats:italic>\u2009&amp;lt;\u2009.001) compared with the 50 to 65 years group after adjustment for sex, race, and performance status. Significantly shorter OS in the younger than 50 years group was confirmed in the Moffitt cohort. The younger than 50 years group had a significantly higher incidence of nausea and vomiting (69.3% vs 57.6% [50-65 years] vs 60.4% [&amp;gt;65 years]; P<\/jats:italic>\u2009=\u2009.02), severe abdominal pain (8.4% vs 3.4% vs 3.5%; P<\/jats:italic>\u2009=\u2009.02), severe anemia (6.1% vs 1.0% vs 1.5%; P<\/jats:italic>\u2009&amp;lt;\u2009.001), and severe rash (2.8% vs 1.2% vs 0.4% P<\/jats:italic>\u2009=\u2009.047). The younger than 50 years group also had earlier onset of nausea and vomiting (1.0 vs 2.1 vs 2.6 weeks; P<\/jats:italic>\u2009=\u2009.01), mucositis (3.6 vs 5.1 vs 5.7 weeks; P<\/jats:italic>\u2009=\u2009.05), and neutropenia (8.0 vs 9.4 vs 8.4 weeks; P<\/jats:italic>\u2009=\u2009.04), and shorter duration of mucositis (0.6 vs 0.9 vs 1.0 weeks; P<\/jats:italic>\u2009=\u2009.006). In the younger than 50 years group, severe abdominal pain and severe liver toxic effects were associated with shorter survival. The Moffitt genomic data showed that the younger than 50 years group had a higher prevalence of CTNNB1<\/jats:italic> mutation (6.6% vs 3.1% vs 2.3%; P<\/jats:italic>\u2009=\u2009.047), ERBB2<\/jats:italic> amplification (5.1% vs 0.6% vs 2.3%; P<\/jats:italic>\u2009=\u2009.005), and CREBBP<\/jats:italic> mutation (3.1% vs 0.9% vs 0.5%; P<\/jats:italic>\u2009=\u2009.05), but lower prevalence of BRAF<\/jats:italic> mutation (7.7% vs 8.5% vs 16.7%; P<\/jats:italic>\u2009=\u2009.002).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of 1959 patients, those with early-onset mCRC showed worse survival outcomes and unique adverse event patterns, which could be partially attributed to distinct genomic profiles. These findings may inform individualized management approaches in patients with early-onset mCRC.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.20035","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T15:35:34Z","timestamp":1687793734000},"page":"e2320035","source":"Crossref","is-referenced-by-count":28,"title":["Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Lingbin","family":"Meng","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa"},{"name":"Division of Medical Oncology, The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Thapa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Delgado","sequence":"additional","affiliation":[{"name":"Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ji","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Knepper","sequence":"additional","affiliation":[{"name":"Department of Personalized Cancer Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joleen M.","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Permuth","sequence":"additional","affiliation":[{"name":"Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"},{"name":"Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian A.","family":"Laber","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"issue":"10","key":"zoi230598r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040.","volume":"14","author":"Xi","year":"2021","journal-title":"Transl Oncol"},{"issue":"17","key":"zoi230598r2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMp1600448","article-title":"Colorectal cancer on the decline\u2014why screening can\u2019t explain it all.","volume":"374","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"26","key":"zoi230598r3","first-page":"884","article-title":"Vital signs: colorectal cancer screening, incidence, and mortality\u2014United States, 2002-2010.","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi230598r4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10620-015-3600-5","article-title":"The impact of screening on colorectal cancer mortality and incidence: has it really made a difference?","volume":"60","author":"Zauber","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"2","key":"zoi230598r5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.gastro.2019.07.055","article-title":"Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults.","volume":"158","author":"Stoffel","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"zoi230598r6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41571-020-00445-1","article-title":"Rising incidence of early-onset colorectal cancer\u2014a call to action.","volume":"18","author":"Akimoto","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"zoi230598r7","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/jnci\/djab124","article-title":"A comprehensive comparison of early-onset and average-onset colorectal cancers.","volume":"113","author":"Cercek","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi230598r8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jamasurg.2014.1756","article-title":"Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010.","volume":"150","author":"Bailey","year":"2015","journal-title":"JAMA Surg"},{"issue":"6","key":"zoi230598r9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.cgh.2010.10.021","article-title":"Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer.","volume":"9","author":"Limburg","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"zoi230598r10","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/ijc.v124:5","article-title":"Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test.","volume":"124","author":"Schofield","year":"2009","journal-title":"Int J Cancer"},{"issue":"12","key":"zoi230598r11","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/cncr.31994","article-title":"Clinical and molecular characterization of early-onset colorectal cancer.","volume":"125","author":"Willauer","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"zoi230598r12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/PAS.0b013e31818afd6b","article-title":"Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.","volume":"33","author":"Yantiss","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"zoi230598r13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.clcc.2017.06.002","article-title":"Early-onset colorectal cancer is distinct from traditional colorectal cancer.","volume":"16","author":"Yeo","year":"2017","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"zoi230598r14","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkab029","article-title":"Nongenetic determinants of risk for early-onset colorectal cancer.","volume":"5","author":"Archambault","year":"2021","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"3","key":"zoi230598r15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000507232","article-title":"Alcohol use and gastrointestinal cancer risk.","volume":"36","author":"Scher\u00fcbl","year":"2020","journal-title":"Visc Med"},{"issue":"2","key":"zoi230598r16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1053\/j.gastro.2020.01.004","article-title":"Risk factors for early-onset colorectal cancer.","volume":"159","author":"Low","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"zoi230598r18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"issue":"13","key":"zoi230598r19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"issue":"28","key":"zoi230598r20","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi230598r21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"zoi230598r22","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi230598r23","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann Oncol"},{"issue":"20","key":"zoi230598r24","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2010.33.5281","article-title":"Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.","volume":"29","author":"Blanke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"36","key":"zoi230598r25","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1200\/JCO.21.02008","article-title":"Early-onset colorectal adenocarcinoma in the IDEA database: treatment adherence, toxicities, and outcomes with 3 and 6 months of adjuvant fluoropyrimidine and oxaliplatin.","volume":"39","author":"Fontana","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi230598r26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jnci\/djab200","article-title":"Survival in young-onset metastatic colorectal cancer: findings from cancer and leukemia group B (Alliance)\/SWOG 80405.","volume":"114","author":"Lipsyc-Sharf","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"zoi230598r27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejca.2022.02.031","article-title":"FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.","volume":"167","author":"Antoniotti","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10","key":"zoi230598r28","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/ijc.v151.10","article-title":"Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: overall and sex-specific outcomes in the Valentino trial.","volume":"151","author":"Raimondi","year":"2022","journal-title":"Int J Cancer"},{"issue":"27","key":"zoi230598r29","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1200\/JCO.2013.54.9329","article-title":"Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.","volume":"32","author":"Lieu","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi230598r30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/jamasurg.2014.3572","article-title":"Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains.","volume":"150","author":"Kneuertz","year":"2015","journal-title":"JAMA Surg"},{"issue":"12","key":"zoi230598r31","doi-asserted-by":"publisher","first-page":"e1846","DOI":"10.1200\/OP.20.01010","article-title":"Care patterns and overall survival in patients with early-onset metastatic colorectal cancer.","volume":"17","author":"Kanter","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"zoi230598r32","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1016\/j.clcc.2019.07.005","article-title":"Effect of body mass index on 5-FU\u2013based chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer; a pooled analysis of 5 randomized trials.","volume":"18","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"zoi230598r33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clcc.2018.12.006","article-title":"Impact of sex on chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer: pooled analysis of 5 randomized trials.","volume":"18","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"11","key":"zoi230598r34","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"31","key":"zoi230598r35","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi230598r36","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"24","key":"zoi230598r37","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting.","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"issue":"15","key":"zoi230598r38","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue-and plasma-based methodologies.","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"zoi230598r39","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(19)30147-5","article-title":"Changes in colorectal cancer incidence in seven high-income countries: a population-based study.","volume":"4","author":"Araghi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"zoi230598r40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nrc2349","article-title":"The distinctive biology of cancer in adolescents and young adults.","volume":"8","author":"Bleyer","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"zoi230598r41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000135","article-title":"Young patients (=35 years old) with colorectal cancer have worse outcomes due to more advanced disease: a 30-year retrospective review.","volume":"93","author":"Fu","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"zoi230598r42","doi-asserted-by":"publisher","first-page":"e2112539","DOI":"10.1001\/jamanetworkopen.2021.12539","article-title":"Analysis of survival among adults with early-onset colorectal cancer in the National Cancer Database.","volume":"4","author":"Cheng","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi230598r43","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/modpathol.2012.61","article-title":"Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.","volume":"25","author":"Chang","year":"2012","journal-title":"Mod Pathol"},{"key":"zoi230598r44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jss.2021.03.040","article-title":"Mismatch repair status correlates with survival in young adults with metastatic colorectal cancer.","volume":"266","author":"van der Heide","year":"2021","journal-title":"J Surg Res"},{"issue":"15","key":"zoi230598r45","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1200\/jco.2008.26.15_suppl.4026","article-title":"Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study.","volume":"26","author":"Kozloff","year":"2008","journal-title":"J Clin Oncol"},{"key":"zoi230598r46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy281.121","article-title":"Interim analysis of the non-interventional study QoLiTrap (AIO-LQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept (AFL)+ FOLFIRI: efficacy according to age group= 65 and> 65 years.","volume":"29","author":"Hofheinz","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi230598r47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/MLR.0000000000000510","article-title":"Trends in the treatment of metastatic colon and rectal cancer in elderly patients.","volume":"54","author":"Bradley","year":"2016","journal-title":"Med Care"},{"issue":"12","key":"zoi230598r48","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/jnci\/djab123","article-title":"Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: an analysis of the ACCENT database.","volume":"113","author":"Jin","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"zoi230598r49","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1200\/JCO.2015.65.0994","article-title":"Racial\/ethnic disparities in survival among patients with young-onset colorectal cancer.","volume":"34","author":"Holowatyj","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi230598r50","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/annonc\/mdz403","article-title":"Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.","volume":"30","author":"Marmorino","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"zoi230598r51","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/carcin\/bgy122","article-title":"Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans.","volume":"39","author":"Xicola","year":"2018","journal-title":"Carcinogenesis"},{"issue":"19","key":"zoi230598r52","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-19-0899","article-title":"Comprehensive genomic landscapes in early and later onset colorectal cancer.","volume":"25","author":"Lieu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"zoi230598r53","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.3390\/cancers12123638","article-title":"Targeting wnt signaling for gastrointestinal cancer therapy: present and evolving views.","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"20","key":"zoi230598r54","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.3390\/cancers14205160","article-title":"Emerging role of ERBB2 in targeted therapy for metastatic colorectal cancer: signaling pathways to therapeutic strategies.","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"zoi230598r17","first-page":"1608","volume-title":"Early-Onset Colorectal Cancer: The Mystery Remains","author":"Eng","year":"2021"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2806375\/meng_2023_oi_230598_1686672061.52201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T15:35:40Z","timestamp":1687793740000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2806375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.20035","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]}}}